ARTICLE | Clinical News
OvaRex: Phase IIb
October 30, 2000 8:00 AM UTC
Additional interim results of AXO's 345-patient placebo-controlled Phase IIb trial showed that patients demonstrating an immune response characterized by the generation of antibodies against the tumor...